Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: A case report

Bach Ardalan; Jose Ignacio Azqueta; Jonathan England; Tiffany Alyssa Eatz

doi:10.1101/mcs.a006108

Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: A case report

Bach Ardalan, Jose Ignacio Azqueta, Jonathan England, Tiffany Alyssa Eatz

Research output: Contribution to journal › Article › peer-review

Abstract

This is the first case report of a 60-yr-old female who underwent therapy for metastatic pancreatic cancer with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). Upon the progression of her disease, she was switched to gemcitabine and nab-paclitaxel. Per genomic sequencing, her tumor was found to be a KRAS wildtype and BRAF V600E mutation, which then warranted treatment with the MEK1 and MEK2 inhibitor, cobimetinib. The patient has achieved a complete response (CR) to a combination of gemcitabine, nab-paclitaxel, and cobimetinib. It has been 16 mo since the start of the treatment, and the patient continues to demonstrate a complete durable response both serologically and radiologically.

Original language	English (US)
Article number	a006108
Journal	Cold Spring Harbor Molecular Case Studies
Volume	7
Issue number	5
DOIs	https://doi.org/10.1101/mcs.a006108
State	Published - Dec 2021
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Genetics
Genetics(clinical)

Access to Document

10.1101/mcs.a006108

Cite this

Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients : A case report. / Ardalan, Bach; Azqueta, Jose Ignacio; England, Jonathan; Eatz, Tiffany Alyssa.

In: Cold Spring Harbor Molecular Case Studies, Vol. 7, No. 5, a006108, 12.2021.

Research output: Contribution to journal › Article › peer-review

@article{e57621463ba14050a3adb7fcf3213f7d,

title = "Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: A case report",

abstract = "This is the first case report of a 60-yr-old female who underwent therapy for metastatic pancreatic cancer with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). Upon the progression of her disease, she was switched to gemcitabine and nab-paclitaxel. Per genomic sequencing, her tumor was found to be a KRAS wildtype and BRAF V600E mutation, which then warranted treatment with the MEK1 and MEK2 inhibitor, cobimetinib. The patient has achieved a complete response (CR) to a combination of gemcitabine, nab-paclitaxel, and cobimetinib. It has been 16 mo since the start of the treatment, and the patient continues to demonstrate a complete durable response both serologically and radiologically. ",

author = "Bach Ardalan and Azqueta, {Jose Ignacio} and Jonathan England and Eatz, {Tiffany Alyssa}",

note = "Publisher Copyright: {\textcopyright} 2021 Ardalan et al.",

year = "2021",

month = dec,

doi = "10.1101/mcs.a006108",

language = "English (US)",

volume = "7",

journal = "Cold Spring Harbor molecular case studies",

issn = "2373-2873",

publisher = "Cold Spring Harbor Laboratory Press",

number = "5",

}

TY - JOUR

T1 - Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients

T2 - A case report

AU - Ardalan, Bach

AU - Azqueta, Jose Ignacio

AU - England, Jonathan

AU - Eatz, Tiffany Alyssa

PY - 2021/12

Y1 - 2021/12

N2 - This is the first case report of a 60-yr-old female who underwent therapy for metastatic pancreatic cancer with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). Upon the progression of her disease, she was switched to gemcitabine and nab-paclitaxel. Per genomic sequencing, her tumor was found to be a KRAS wildtype and BRAF V600E mutation, which then warranted treatment with the MEK1 and MEK2 inhibitor, cobimetinib. The patient has achieved a complete response (CR) to a combination of gemcitabine, nab-paclitaxel, and cobimetinib. It has been 16 mo since the start of the treatment, and the patient continues to demonstrate a complete durable response both serologically and radiologically.

AB - This is the first case report of a 60-yr-old female who underwent therapy for metastatic pancreatic cancer with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). Upon the progression of her disease, she was switched to gemcitabine and nab-paclitaxel. Per genomic sequencing, her tumor was found to be a KRAS wildtype and BRAF V600E mutation, which then warranted treatment with the MEK1 and MEK2 inhibitor, cobimetinib. The patient has achieved a complete response (CR) to a combination of gemcitabine, nab-paclitaxel, and cobimetinib. It has been 16 mo since the start of the treatment, and the patient continues to demonstrate a complete durable response both serologically and radiologically.

UR - http://www.scopus.com/inward/record.url?scp=85119311338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119311338&partnerID=8YFLogxK

U2 - 10.1101/mcs.a006108

DO - 10.1101/mcs.a006108

M3 - Article

C2 - 34667063

AN - SCOPUS:85119311338

VL - 7

JO - Cold Spring Harbor molecular case studies

JF - Cold Spring Harbor molecular case studies

SN - 2373-2873

IS - 5

M1 - a006108

ER -

Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: A case report

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this